A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ACCLAIM
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 14 Aug 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.